Arena Pharmaceuticals Inc (NASDAQ:ARNA) Q4 2019 Earnings Conference Call - Final Transcript
Feb 26, 2020 • 04:30 pm ET
Good day, everyone, and welcome to Arena Pharmaceuticals Financial Results and Corporate Update Conference call.
[Operator Instructions] I will now turn the call over to Kevin Lind, Chief Financial Officer of Arena. Please go ahead.
Kevin R. Lind
Good afternoon. Before we begin, I'd like to remind you that we'll make forward-looking statements that involve risks and uncertainties, including statements about our objectives, plans, goals, strategy, expectations, beliefs focus, regulatory activities, R&D programs, product candidates and operations and those of our collaborators and licensees and other statements that are not historical facts. These statements are made in the context of the risks and uncertainties that are discussed in our filings with the U.S. Securities and Exchange Commission, which can be found on the SEC website at www.sec.gov and include risks related to timing of preclinical and clinical studies, including patient recruitment for clinical trials, which is competitive and challenging and may take longer than we project. Preclinical and clinical study results and the timing of such results, which may not be as expected or sufficient for further development, regulatory approval or commercialization, timing and outcomes of regulatory interactions and decisions collaboration and licensing activities and the amount allocation and projected use of our NOL financial and other resources. Our actual results may differ materially from our forward-looking statements.
Now I'd like to turn the call over to Amit.
Amit D. Munshi
Thanks, Kevin. Hi, everyone, and thanks for joining our call today. Today, I'll go through a corporate and management overview and then Preston will provide pipeline updates, and we'll conclude with a financial review of the fourth quarter and full year 2019. In 2019, we made exceptionally strong progress across all fronts in the company, and we importantly maintained that cadence into 2020. Critically, we remain on track with our near and midterm operational objectives including delivering up to eight major data readouts between 2020 and 2021. Last month, we reviewed our strategic plan that sets the foundation for the future of Arena, as we enter the next stage of the evolution of the company. We outlined two specific and distinct areas of opportunity. First, expanding the value of the etrasimod into additional indications; and second, further unlocking the value of the historical Arena G protein coupled receptor, or GPCR research platform. Our new strategic footprint, ongoing programs and new initiatives made for catalyst which horizon for the company. I'm expanding the value of etrasimod. We continue to believe that a once-daily oral agent with etrasimod's profile offers tremendous promise in the treatment of a broad range of immune-mediated inflammatory diseases. To that end, we are initiating two new programs, both in the area of current therapeutic focus. In GI, a Phase IIb program in eosinophilic esophagitis or EOE and in dermatology, a Phase II program in alopecia areata or AA. We expect to initiate both these trials this year, and Preston will provide more details on each of these programs later on this call.
To unlock additional value, we turn our focus to harvesting the